Bradley Merrill Thompson Quoted in “Trump’s Proposal to Increase FDA User Fees Could Impact Small Digital Health Innovators”

FierceHealthcare

Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in FierceHealthcare, in “Trump’s Proposal to Increase FDA User Fees Could Impact Small Digital Health Innovators,” by Evan Sweeney.

Following is an excerpt:

Bradley Merrill Thompson, an FDA attorney with Epstein Becker Green in Washington, D.C., said it’s impossible to know what the administration has in mind and questioned the substance behind the budget’s reference to a streamlined regulatory process.

But he echoed concerns that higher user fees would have a bigger impact on digital startups.

“A big concern will be small companies that don't have much cash to spend on user fees,” he said in an interview. “Small companies have been an enormous source of innovation in digital health.”